within Pharmacolibrary.Drugs.ATC.L;

model L02AE04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.025666666666666667,
    adminDuration  = 600,
    adminMass      = 0.00375,
    adminCount     = 1,
    Vd             = 0.0292,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Triptorelin is a synthetic decapeptide agonist analogue of gonadotropin-releasing hormone (GnRH), used primarily for the treatment of advanced prostate cancer, central precocious puberty, endometriosis, and uterine fibroids. It works by suppressing pituitary gonadotropin secretion, thus lowering sex hormone levels. Triptorelin is approved and in use today as a depot injection in various indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult males with advanced prostate cancer following single intramuscular dose of 3.75 mg depot formulation; non-compartmental analysis.</p><h4>References</h4><ol><li><p>Keating, GM (2010). Triptorelin embonate (6-month formulation). <i>Drugs</i> 70(3) 347–353. DOI:<a href=&quot;https://doi.org/10.2165/11202230-000000000-00000&quot;>10.2165/11202230-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20166771/&quot;>https://pubmed.ncbi.nlm.nih.gov/20166771</a></p></li><li><p>Han, J, et al., &amp; Di, X (2014). An analytical strategy to characterize the pharmacokinetics and pharmacodynamics of triptorelin in rats based on simultaneous LC-MS/MS analysis of triptorelin and endogenous testosterone in rat plasma. <i>Analytical and bioanalytical chemistry</i> 406(9-10) 2457–2465. DOI:<a href=&quot;https://doi.org/10.1007/s00216-014-7616-z&quot;>10.1007/s00216-014-7616-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24510211/&quot;>https://pubmed.ncbi.nlm.nih.gov/24510211</a></p></li><li><p>Durand, A, et al., &amp; Dutailly, P (2017). Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation . <i>Hormone research in paediatrics</i> 87(4) 224–232. DOI:<a href=&quot;https://doi.org/10.1159/000456545&quot;>10.1159/000456545</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28334719/&quot;>https://pubmed.ncbi.nlm.nih.gov/28334719</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L02AE04;
